Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 104 of 104 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/12/19
End: 02/28/25
Due: 02/28/26
Phase: N/A
Priority: Normal
Start: 04/07/17
End: 11/18/19
Due: 11/18/20
Phase: N/A
Priority: Normal
Start: 05/31/10
End: 05/31/13
Due: 05/31/14
Phase: N/A
Priority: Normal
Start: 05/05/23
End: 09/30/25
Due: 09/30/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Window of Opportunity Study in Colorectal Cancer | NCT03984578 | National Cancer Centre, Singapore | user2@example.com | None | 2019-06-12 | 2025-02-28 | 2026-02-28 | - | - | 2025-07-14 |
| Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer | NCT03091491 | National Cancer Centre, Singapore | user2@example.com | None | 2017-04-07 | 2019-11-18 | 2020-11-18 | - | - | 2025-07-14 |
| A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer | NCT01736410 | National Cancer Centre, Singapore | user2@example.com | None | 2010-05-31 | 2013-05-31 | 2014-05-31 | - | - | 2025-07-14 |
| Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in | NCT05198479 | National Cancer Centre, Singapore | user2@example.com | None | 2023-05-05 | 2025-09-30 | 2026-09-30 | - | - | 2025-07-14 |